LOL!! Yes, I said that. To me, it doesn't matter too much what the analysts say, not even what management guides to. Demand will be the determinant. I think doctors will rejoice in discovering what this drug can do for their patients, just as I thought it was capable of doing for my wife, if it was better understood, and had regulatory approval, which it fully deserves.
This is a fine biotech with a lot of promising technology. Too many people were counting on early approval and it didn't happen I'm consequently the quick money folks sold off and dropped this way below where we should be. I think I bought my first shares at 15 bought more at 6, and added today.